Daré Bioscience, Inc. (NASDAQ:DARE) Sees Large Growth in Short Interest

Daré Bioscience, Inc. (NASDAQ:DARE) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 86,600 shares, a growth of 50.9% from the December 15th total of 57,400 shares. Based on an average trading volume of 50,200 shares, the short-interest ratio is currently 1.7 days. Currently, 1.0% of the company’s shares are sold short.

Hedge Funds Weigh In On Daré Bioscience

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC raised its position in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 778,700 shares of the biotechnology company’s stock after purchasing an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned 9.25% of Daré Bioscience worth $262,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 6.70% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Daré Bioscience in a research note on Tuesday, December 17th.

Daré Bioscience Price Performance

Shares of Daré Bioscience stock traded up $0.01 during trading hours on Friday, hitting $3.34. The company’s stock had a trading volume of 11,893 shares, compared to its average volume of 22,963. The company has a market capitalization of $29.06 million, a PE ratio of -5.65 and a beta of 1.28. The stock has a 50 day moving average of $3.30 and a 200 day moving average of $3.42. Daré Bioscience has a 12 month low of $2.67 and a 12 month high of $7.56.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.